当前位置：Public Access >页面
Chinese/English
Efficacy and safety of tislelizumab plus anlotinib in the treatment of cervical cancer resistant to standard therapy: A prospective, single-arm, open labelled phase II clinical trial
Filter Options
Patient No. Patient Name Patient Gender
Sitting Education Date of enrollment FromTo
       More Options
Patient No Gender Date of enrollment Sitting Creater Operate
NO participants recorded。

提示：推荐使用chrome浏览器 并且在宽屏显示分辨率下使用系统。

Copyright(c) (2010-2013) .All rights reserved.临床试验公共管理平台 版权所有